Estradiol Vaginal Cream 0.03% — Local Estrogen Support

Route: Intravaginal — cream applied using a calibrated applicator.

• Insert the prescribed amount (typically 0.5–1 g) into the vagina using the provided applicator at bedtime or as directed by the prescriber.
• Remain recumbent for a few minutes after insertion to minimize leakage and maximize mucosal contact.
• Application frequency (daily for an initial period, then 2–3 times per week maintenance) is prescribed by the clinician.
• Wash the applicator with mild soap and warm water after each use.
• Avoid applicator-based intercourse on application days; patients should be counseled on the interaction between cream and latex barrier contraceptives (may degrade latex).

Dosing frequency and duration are prescriber-determined. General clinical reference points for low-concentration vaginal estradiol:

• An initial daily application for 2–4 weeks, followed by maintenance dosing (2–3 times per week) is a common clinical approach for vaginal atrophy.
• The amount per application is typically 0.5–1 g of cream; confirmed by applicator markings and prescriber direction.
• At 0.03%, systemic absorption is low but should be considered in patients with concerns about systemic estrogen exposure.
• The need for concurrent progestogen with low-dose local vaginal estrogen is controversial; prescribers follow current clinical guidelines and individual patient risk stratification.

• Estradiol 0.03% (vaginal): Locally applied estradiol is absorbed through the vaginal mucosa and binds ERα and ERβ in vaginal epithelial cells, increasing epithelial thickness, glycogen content, and superficial cell maturation. Estrogen signaling promotes restoration of the lactobacillus-dominant vaginal microbiome, lowering pH toward the normal acidic range (3.8–4.5). ERβ activation in urethral epithelium supports urethral mucosal integrity and may reduce urgency. At 0.03%, systemic serum estradiol elevations are minimal but may not remain entirely below the endogenous postmenopausal range — a consideration for patients with estrogen-sensitive conditions.

Clinical Context: Low-concentration vaginal estradiol (0.03%) is indicated for the local treatment of genitourinary syndrome of menopause (GSM): vaginal dryness, dyspareunia, recurrent urinary tract infections, and urinary urgency related to atrophic changes. This concentration is lower than the FDA-approved 0.01% (0.1 mg/g) commercially available estradiol vaginal cream applied at 2–4 g/dose; the compounded 0.03% concentration at lower gram volumes may be designed to achieve a comparable or tailored local estradiol dose per application. Prescribers should confirm intended dosing strategy.

Monitoring Considerations:

• Clinical symptom reassessment at 4–8 weeks and periodically thereafter.
• Vaginal cytology (maturation index) may be used to confirm tissue response.
• Endometrial surveillance: current guidelines suggest that very-low-dose vaginal estrogen does not typically require progestogen in non-hysterectomized women, but individual risk assessment is required.
• Serum estradiol if systemic exposure concerns arise.

Contraindications:

• Known or suspected estrogen-dependent malignancies (breast, endometrial cancer).
• Undiagnosed abnormal genital bleeding.
• Active or history of thromboembolic events (DVT, PE, stroke, MI).
• Active liver disease.
• Known hypersensitivity to estradiol or cream components.

Warnings & Precautions:

• Systemic absorption: Although limited at low concentrations, some systemic absorption occurs — caution in patients where systemic estrogen is contraindicated.
• Endometrial effects: Progestogen may not be routinely required at very low vaginal doses, but prescriber judgment applies based on patient history and local estrogen preparation specifics.
• Latex incompatibility: Vaginal cream may weaken latex condoms and diaphragms.

Drug Interactions:

• CYP3A4 inducers/inhibitors may affect minimal systemic absorption. Latex contraceptive degradation is a mechanical interaction.

Common Side Effects: Vaginal discharge, mild local irritation or burning (particularly early in therapy), application site discomfort, and headache. Systemic effects are unlikely at this low concentration and low application volume but are possible.

Store at controlled room temperature (20–25°C / 68–77°F); do not freeze. Keep in the original tube with cap tightly closed, away from heat, moisture, and direct light. Store out of reach of children. Observe the beyond-use date assigned by Genesis Compounding; do not use after this date.

How is this cream different from a commercially available estradiol vaginal cream?

FDA-approved estradiol vaginal cream (e.g., Estrace® at 0.01%) is typically applied in 2–4 gram doses, delivering 0.2–0.4 mg of estradiol per application. This 0.03% compounded preparation is a different concentration; your prescriber has specified the dose per application. Confirm the intended grams per application and frequency with Genesis Compounding or your prescriber.

Will this cream be absorbed systemically?

Low-dose vaginal estradiol preparations have limited systemic absorption compared to oral or transdermal products. However, some absorption does occur, particularly with higher volumes. At 0.03% in small doses, systemic exposure is expected to be low, but not zero. Patients with concerns about any systemic estrogen exposure should discuss this with their prescriber.

Do I need a progestogen with this cream?

Current guidelines indicate that very-low-dose local vaginal estradiol typically does not require routine endometrial progestogen protection. However, individual risk assessment by your prescriber is required — particularly for women with prior endometrial conditions or higher systemic absorption.

Is this FDA-approved?

This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding and is not FDA-approved as a finished compounded drug product.

Can I use lubricants or moisturizers alongside this cream?

Yes — vaginal moisturizers and lubricants can be used as adjuncts for symptomatic relief. Apply on non-cream application days. Avoid oil-based products with latex-containing contraceptives.